Log in
NYSE:PFE

Pfizer Stock Forecast, Price & News

$36.53
-0.07 (-0.19 %)
(As of 11/25/2020 12:00 AM ET)
Add
Compare
Today's Range
$36.24
Now: $36.53
$36.56
50-Day Range
$35.28
MA: $37.05
$39.20
52-Week Range
$27.88
Now: $36.53
$41.99
Volume26.96 million shs
Average Volume30.40 million shs
Market Capitalization$203.05 billion
P/E Ratio14.50
Dividend Yield4.15%
Beta0.66
Pfizer Inc. develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and pain under the Eliquis, Chantix/Champix, and Premarin family brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Sutent, Xtandi, Xalkori, Inlyta, Braftovi + Mektovi brands; and sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Vfend, and Zithromax brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, and tick-borne encephalitis under the Prevnar 13/Prevenar 13 (pediatric/adult), FSME-IMMUN, Nimenrix, and Trumenba brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, and Eucrisa brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, Genotropin, and Refacto AF/Xyntha brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration and/or co-promotion agreements with Bristol-Myers Squibb Company and Astellas Pharma US, Inc.; a licensing agreement with Akcea Therapeutics, Inc; a strategic alliance with Verily Life Sciences LLC; collaboration agreements with Merck KGaA and Valneva SE; a clinical trial collaboration and supply agreement with IDEAYA Biosciences, Inc.; a material transfer and collaboration agreement with BioNTech SE; a clinical supply collaboration with Jiangsu Alphamab Biopharmaceuticals Co., Ltd; a research collaboration and license agreement with BioInvent International AB; and a multi-target drug discovery collaboration with Sosei Group Corporation. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Read More
Pfizer logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.2Community Rank: 2.9Dividend Strength: 3.3Insider Behavior: 3.3Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.60 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
CUSIP71708110
Phone212-733-2323
Employees88,300

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$51.75 billion
Cash Flow$3.97 per share
Book Value$11.46 per share

Profitability

Net Income$16.27 billion

Miscellaneous

Outstanding Shares5,558,396,000
Market Cap$203.05 billion
Next Earnings Date1/26/2021 (Estimated)
OptionableOptionable
$36.53
-0.07 (-0.19 %)
(As of 11/25/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive PFE News and Ratings via Email

Sign-up to receive the latest news and ratings for PFE and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Pfizer (NYSE:PFE) Frequently Asked Questions

How has Pfizer's stock price been impacted by COVID-19 (Coronavirus)?

Pfizer's stock was trading at $32.17 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, PFE stock has increased by 13.6% and is now trading at $36.53.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Pfizer?

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pfizer in the last year. There are currently 9 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Pfizer
.

What stocks does MarketBeat like better than Pfizer?

Wall Street analysts have given Pfizer a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Pfizer wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Pfizer's next earnings date?

Pfizer is scheduled to release its next quarterly earnings announcement on Tuesday, January 26th 2021.
View our earnings forecast for Pfizer
.

How were Pfizer's earnings last quarter?

Pfizer Inc. (NYSE:PFE) posted its earnings results on Tuesday, October, 27th. The biopharmaceutical company reported $0.72 EPS for the quarter, topping analysts' consensus estimates of $0.71 by $0.01. The biopharmaceutical company earned $12.13 billion during the quarter, compared to analyst estimates of $12.30 billion. Pfizer had a return on equity of 25.11% and a net margin of 28.80%. The business's quarterly revenue was down 4.3% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.75 earnings per share.
View Pfizer's earnings history
.

How often does Pfizer pay dividends? What is the dividend yield for Pfizer?

Pfizer announced a quarterly dividend on Thursday, September 24th. Shareholders of record on Friday, November 6th will be paid a dividend of $0.38 per share on Tuesday, December 1st. This represents a $1.52 annualized dividend and a yield of 4.16%. The ex-dividend date is Thursday, November 5th.
View Pfizer's dividend history
.

How will Pfizer's stock buyback program work?

Pfizer announced that its board has initiated a share repurchase program on Friday, December 14th 2018, which allows the company to repurchase $10,000,000,000.00 in shares, according to EventVestor. This repurchase authorization allows the company to repurchase up to 3.8% of its stock through open market purchases. Stock repurchase programs are typically a sign that the company's leadership believes its shares are undervalued.

What guidance has Pfizer issued on next quarter's earnings?

Pfizer updated its FY20 earnings guidance on Tuesday, October, 27th. The company provided EPS guidance of $2.88-$2.93 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $2.72. The company issued revenue guidance of $48.8-$49.5 billion, compared to the consensus revenue estimate of $48.11 billion.

What price target have analysts set for PFE?

14 Wall Street analysts have issued 1 year price targets for Pfizer's stock. Their forecasts range from $24.00 to $53.00. On average, they expect Pfizer's share price to reach $40.00 in the next twelve months. This suggests a possible upside of 9.5% from the stock's current price.
View analysts' price targets for Pfizer
.

Are investors shorting Pfizer?

Pfizer saw a increase in short interest in October. As of October 30th, there was short interest totaling 45,930,000 shares, an increase of 13.6% from the October 15th total of 40,440,000 shares. Based on an average daily volume of 26,830,000 shares, the short-interest ratio is currently 1.7 days.
View Pfizer's Short Interest
.

Who are some of Pfizer's key competitors?

What other stocks do shareholders of Pfizer own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Pfizer investors own include AT&T (T), Johnson & Johnson (JNJ), Cisco Systems (CSCO), Intel (INTC), Verizon Communications (VZ), AbbVie (ABBV), The Walt Disney (DIS), Exxon Mobil (XOM), NVIDIA (NVDA) and JPMorgan Chase & Co. (JPM).

Who are Pfizer's key executives?

Pfizer's management team includes the following people:
  • Dr. Albert Bourla D.V.M., DVM, Ph.D., Chairman & CEO (Age 58, Pay $5.84M)
  • Mr. John D. Young, Group Pres & Chief Bus. Officer (Age 55, Pay $3.36M)
  • Mr. Frank A. D'Amelio, CFO & EVP of Global Supply & Bus. Operations (Age 62, Pay $3.84M)
  • Dr. Mikael Dolsten, Chief Scientific Officer and Pres of Worldwide Research, Devel. & Medical (Age 61, Pay $3.66M)
  • Ms. Jennifer B. Damico, Sr. VP, Controller & Principal Accounting Officer (Age 52)
  • Ms. Lidia L. Fonseca, Exec. VP and Chief Digital & Technology Officer (Age 51)
  • Mr. Charles E. Triano, Sr. VP of Investor Relations
  • Mr. Douglas M. Lankler, Exec. VP & Gen. Counsel (Age 54)
  • Mr. Rady A. Johnson, Exec. VP and Chief Compliance, Quality & Risk Officer (Age 58)
  • Dr. Alexander Rod MacKenzie, Chief Devel. Officer & Exec. VP of Global Product Devel. (Age 60)

What is Pfizer's stock symbol?

Pfizer trades on the New York Stock Exchange (NYSE) under the ticker symbol "PFE."

Who are Pfizer's major shareholders?

Pfizer's stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (7.46%), State Street Corp (5.20%), Morgan Stanley (0.83%), Charles Schwab Investment Management Inc. (0.72%), Massachusetts Financial Services Co. MA (0.69%) and Nuveen Asset Management LLC (0.55%). Company insiders that own Pfizer stock include Alexander R Mackenzie, Dawn Rogers, Douglas M Lankler, Frank A Damelio, Jennifer B Damico, Mikael Dolsten, Pfizer Inc, Rady A Johnson, Ronald E Blaylock and Scott Gottlieb.
View institutional ownership trends for Pfizer
.

Which major investors are selling Pfizer stock?

PFE stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., State Street Corp, UBS Asset Management Americas Inc., AQR Capital Management LLC, TD Asset Management Inc., KBC Group NV, AXA S.A., and LSV Asset Management. Company insiders that have sold Pfizer company stock in the last year include Douglas M Lankler, and Jennifer B Damico.
View insider buying and selling activity for Pfizer
.

Which major investors are buying Pfizer stock?

PFE stock was purchased by a variety of institutional investors in the last quarter, including Natixis, Morgan Stanley, Robeco Institutional Asset Management B.V., Retirement Systems of Alabama, Jupiter Asset Management Ltd., First Trust Advisors LP, BNP PARIBAS ASSET MANAGEMENT Holding S.A., and DekaBank Deutsche Girozentrale. Company insiders that have bought Pfizer stock in the last two years include Pfizer Inc, Ronald E Blaylock, and Scott Gottlieb.
View insider buying and selling activity for Pfizer
.

How do I buy shares of Pfizer?

Shares of PFE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Pfizer's stock price today?

One share of PFE stock can currently be purchased for approximately $36.53.

How big of a company is Pfizer?

Pfizer has a market capitalization of $203.05 billion and generates $51.75 billion in revenue each year. The biopharmaceutical company earns $16.27 billion in net income (profit) each year or $2.95 on an earnings per share basis. Pfizer employs 88,300 workers across the globe.

What is Pfizer's official website?

The official website for Pfizer is www.pfizer.com.

How can I contact Pfizer?

Pfizer's mailing address is 235 EAST 42ND STREET, NEW YORK NY, 10017. The biopharmaceutical company can be reached via phone at 212-733-2323.

This page was last updated on 11/27/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.